EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Pharmacokinetic Variability of Amlodipine Serum Concentration and Effect on Blood Pressure in Patients Treated for Hypertension

Stine Rognstad iD, Camilla L Søraas, Cathrine Brunborg, Lene V Halvorsen, Karl Marius Brobak, Eirik Olsen, Ola U Bergland, Arleen Aune, Silja S Tuv, Anja Camilla Svarstad, Per Erik Clasen, Renate Haldsrud und 3 weitere

Pharmacology Research & Perspectives · 2025

DOI: 10.1002/prp2.70140 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Pharmacology Research & Perspectives, 2025. Verfasst von Stine Rognstad und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Oslo University Hospital, Oslo, Norway. Hauptthemen laut MEDLINE: Amlodipine, Antihypertensive Agents, Blood Pressure, Calcium Channel Blockers. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The Research Council of Norway, Norges Forskningsråd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We investigated the effects of age, sex, BMI, total number of prescribed daily pills, common biomarkers, and CYP3A4/5 polymorphisms on dose‐adjusted amlodipine concentration (CDR) in hypertensive patients. We also examined associations between the same covariates, dose, and serum amlodipine concentrations with uncontrolled hypertension. Amlodipine concentrations were measured in 471 patients treated with ≥ 2 antihypertensive drugs, with 50% having uncontrolled hypertension (daytime ambulatory blood pressure ≥ 135 mmHg). CYP analyses were performed in a subgroup of 258 patients, 82% of these uncontrolled. Women used lower daily doses ( p < 0.001) and had higher CDR ( p < 0.001) than men. CDR increased with age ( p < 0.001), reduced kidney function ( p < 0.001) and CYP3A4*22 allele ( p = 0.006). Patients with uncontrolled hypertension had lower CDR ( p = 0.014). Women were half as likely as men to have uncontrolled hypertension ( p = 0.002). At the group level, a 20 nmol/L increase in concentration, corresponding to adjustment from 5 to 10 mg, was associated with a 16.5% decreased probability of uncontrolled hypertension. Female sex, increasing age, reduced kidney function, and reduced CYP3A4 activity increased amlodipine CDR. The included covariates explained 41% of the amlodipine concentration variability. Females had a reduced probability of uncontrolled hypertension, and increased amlodipine concentration was associated with decreased probability of uncontrolled hypertension. We suggest using TDM of amlodipine as an aid for clinical decision‐making in cases of unsatisfactory treatment response, to identify possible non‐adherence or pharmacokinetic deviations. Trial Registration: ClinicalTrials.gov identifier: NCT03209154

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmlodipineAntihypertensive AgentsBlood PressureCalcium Channel BlockersHypertensionAdultAgedFemaleHumansMaleMiddle AgedAge FactorsCytochrome P-450 CYP3ADose-Response Relationship, DrugSex Factors

Stichwörter der Autor:innen

amlodipineantihypertensive drugsblood pressurepharmacokinetictherapeutic drug monitoring

Substanzen

AmlodipineAntihypertensive AgentsCalcium Channel BlockersCYP3A4 protein, humanCYP3A5 protein, humanCytochrome P-450 CYP3A

Autor:innen und Institutionen

  • Department of Pharmacology, Oslo University Hospital, Oslo, Norway.
  • Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Section for Cardiovascular and Renal Research, Oslo University Hospital Ullevål, Oslo, Norway.
  • Section for Environmental and Occupational Medicine, Oslo University Hospital Ullevål, Oslo, Norway.
  • Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital, Oslo, Norway.
  • Department of Nephrology, Oslo University Hospital Ullevål, Oslo, Norway.

ORCID-Profile: Stine Rognstad

Förderung

  • The Research Council of Norway
  • Norges Forskningsråd

Zitieren

APA

Rognstad, S., Søraas, C. L., Brunborg, C., Halvorsen, L. V., Brobak, K. M., Olsen, E., Bergland, O. U., Aune, A., Tuv, S. S., Svarstad, A. C., Clasen, P. E., Haldsrud, R., Larstorp, A. C. K., Helland, A., & Opdal, M. S. (2025). Pharmacokinetic Variability of Amlodipine Serum Concentration and Effect on Blood Pressure in Patients Treated for Hypertension. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70140

Vancouver

Rognstad S, Søraas CL, Brunborg C, Halvorsen LV, Brobak KM, Olsen E, et al. Pharmacokinetic Variability of Amlodipine Serum Concentration and Effect on Blood Pressure in Patients Treated for Hypertension. Pharmacology Research & Perspectives. 2025. doi:10.1002/prp2.70140

BibTeX
@article{Rognstad2025,
  author = {Rognstad, Stine and Søraas, Camilla L and Brunborg, Cathrine and Halvorsen, Lene V and Brobak, Karl Marius and Olsen, Eirik and Bergland, Ola U and Aune, Arleen and Tuv, Silja S and Svarstad, Anja Camilla and Clasen, Per Erik and Haldsrud, Renate and Larstorp, Anne Cecilie K and Helland, Arne and Opdal, Mimi Stokke},
  title = {Pharmacokinetic Variability of Amlodipine Serum Concentration and Effect on Blood Pressure in Patients Treated for Hypertension},
  journal = {Pharmacology Research & Perspectives},
  year = {2025},
  doi = {10.1002/prp2.70140}
}
Kostenlos starten →